Translational Pharmaceutics®

We are very excited with the results of our first human study... We have been able to leverage Quotient Sciences’ Translational Pharmaceutics® platform to gain rapid access to the clinic, helping deliver these favorable results in a smooth and rapid fashion.

Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics® approach. The project was successful, and we were generally impressed by the skill sets, professionalism, and courtesy of Quotient Sciences' scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects.

Leveraging an integrated compounding pharmacy approach under the Translational Pharmaceutics® platform saved us over a million dollars because we didn’t need to invest in scaling up peptide synthesis. We were able to make just the right amount of drug product needed to achieve the results we were looking for.

I knew that traditional manufacture and release would make it impossible for us to clinically determine the correct nafamostat component of our drug product. Quotient Sciences explained to me how their Translational Pharmaceutics® platform could reduce our development timeline by defining a design space for ER release rate, ER/IR ratio, and nafamostat dose. Additionally, they could integrate real-time adaptive manufacturing with clinical testing to rapidly test the variables within the design space and optimize the nafamostat formulation.